Compare with:

It seems you have disabled JavaScript - please enable it to access all features of Wikidi.

Tositumomab

Drug
	Pharmacological class	CD20-directed Radiotherapeutic Antibody
	Legal status	Prescription drug
	Marketed formulations	Tositumomab 14,14 kit Tositumomab i-131 0.61 injection Tositumomab i-131 5.6 injection
	Mechanism of action	CD20-directed Antibody Interaction Radiopharmaceutical Activity
	Active moieties	Tositumomab


Drug ingredient
	Active ingredient of formulation	Tositumomab 14,14 kit
	Active moiety of formulation	Tositumomab 14,14 kit Tositumomab i-131 0.61 injection Tositumomab i-131 5.6 injection
	Active moiety of drug	Tositumomab Tositumomab i-131
	More specific ingredient	Tositumomab i-131


NCI Term
	URI	ncicb.nci.nih.gov


BV: Therapeutic
	Indication or disease	Follicular lymphoma (On the market)
	Target/Biomolecule of Interest	CD20


BV: Product
	Developed by	Corixa
	Technology involved	Monoclonal Antibody Murine Monoclonal Antibody Radioimmunotherapy
	Brand Names	Bexxar
	Stage of development	On the market

Edit this page

Source: Tositumomab on Freebase licensed under CC-BY